Maat Pharma SA
PAR:MAAT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
M
|
Maat Pharma SA
PAR:MAAT
|
FR |
|
M
|
MAG Holdings Berhad
KLSE:MAGNUM
|
MY |
|
E
|
EEMS Italia SpA
MIL:EEMS
|
IT |
|
A
|
Aboitiz Equity Ventures Inc
XPHS:AEV
|
PH |
|
Ladder Capital Corp
NYSE:LADR
|
US |
|
Ackermans & Van Haaren NV
XBRU:ACKB
|
BE |
|
EQUUS Total Return Inc
NYSE:EQS
|
US |
Maat Pharma SA
Maat Pharma SA operates as a clinical-stage microbiome therapeutics company. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 43 full-time employees. The company went IPO on 2021-11-08. The firm specializes in the microbiome therapy that is aimed to treatment of Gut Microbiota alteration (Dysbiosis) using patient-specific biotherapeutics in patients with serious medical conditions. Its MaaT Microbiome Restoration Therapy (MMRB) discovery and analysis platform supports the evaluation of drug candidates, the determination of new disease targets and the identification of biomarkers for microbiome-related conditions.
Maat Pharma SA operates as a clinical-stage microbiome therapeutics company. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 43 full-time employees. The company went IPO on 2021-11-08. The firm specializes in the microbiome therapy that is aimed to treatment of Gut Microbiota alteration (Dysbiosis) using patient-specific biotherapeutics in patients with serious medical conditions. Its MaaT Microbiome Restoration Therapy (MMRB) discovery and analysis platform supports the evaluation of drug candidates, the determination of new disease targets and the identification of biomarkers for microbiome-related conditions.
